Redefining the field through Legacy, Expertise, and Innovation.
Onconetics was founded in honor of Dieter Gruenert, Ph.D., an intended Co-Founder, who passed away in April, 2016. Dr. Gruenert was a leader in gene therapy research creating many fundamental technologies used throughout the world. His son, Luke Gruenert, developed Onconetics’ technology while working in Dr. Gruenert’s lab at UCSF. With Onconetics, Luke continues Dr. Gruenert’s legacy by pursuing their shared vision of a cancer free world.
Onconetics is a purpose-driven company developing the world’s first targeted gene therapy platform. They are pioneering a revolution in drug development that will change the paradigm of cancer treatment. Onconetics is a graduate of the IndieBio Accelerator Program’s 6th batch, during which the team generated proof of concept data for their approach to develop highly specific gene therapies targeting cancer. Onconetics’ technology enables the development of smart gene therapies that specifically target cancer cells without targeting other healthy cells in the body. Currently, the team is working to optimize and expand its platform and is expecting to have its breast cancer therapy in the clinic by 2022.